Investigating the long-term effects of orlistat for treating a rare lipid disorder
Official title: Long term efficacy and safety of orlistat for type 1 hyperlipoproteinemia: a randomized, double-blind, placebo-controlled trial
Funded at Ut Southwestern Medical Center · NIH-11094936 · Data updated 2026-11-12
This study is looking at how well the medication orlistat works and how safe it is for both kids and adults with Type I hyperlipoproteinemia, a condition that causes very high triglyceride levels, by checking their triglyceride levels and any side effects over time.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $436,509 |
| NIH project number | 5R33HL166373-03 |
| Project ID | NIH-11094936 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Type I hyperlipoproteinemia, including both children and adults.
✕Less likely to help
Patients who do not have Type I hyperlipoproteinemia or those who are already effectively managing their triglyceride levels with other treatments may not benefit from this research.
What this research studies
This research focuses on Type I hyperlipoproteinemia, a rare metabolic disorder that leads to extremely high triglyceride levels. The study aims to evaluate the long-term efficacy and safety of orlistat, a medication that inhibits intestinal lipase, in both children and adults suffering from this condition. Participants will be monitored for changes in triglyceride levels and potential side effects over an extended period. The research employs a randomized, double-blind, placebo-controlled trial design to ensure reliable results.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with Type I hyperlipoproteinemia, potentially reducing their triglyceride levels and associated health risks.
How similar studies have gone: Preliminary data from earlier trials using orlistat in young patients with this condition showed promising results, indicating that this approach may be effective.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Garg, Abhimanyu — Ut Southwestern Medical Center
- Study coordinator: Garg, Abhimanyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.